Navigation Links
Apricoxib Prolongs Time-to-Progression and Overall Survival in Biomarker-Selected NSCLC Patients
Date:6/6/2011

e United States. In the APRiCOT-L study, Tragara utilized a functional biomarker known as PGEM (a urinary metabolite of PGE2, the pro-inflammatory product of COX-2 activity) to select patients for inclusion into the trial in order to identify the patient population with the best chance of benefitting from apricoxib therapy. The patient selection process included an open-label five-day apricoxib run-in period where baseline and day five urine samples were collected from patients.

Patients with a 50% or greater PGEM decrease from baseline were eligible for randomization if all other eligibility criteria were met.

Time-to-progression was not statistically significantly different than erlotinib alone for the overall population. Safety profiles of the two arms were similar. The most common adverse events reported were of the skin and gastrointestinal tract, similar to the reported toxicity profile of erlotinib alone. Most events were mild to moderate.

"We are very pleased with the efficacy and safety outcomes of APRiCOT-L and the operational ease of employing the patient selection strategy," said Sara Zaknoen, M.D., chief medical officer, Tragara Pharmaceuticals, Inc. "We believe that apricoxib represents an important new potential treatment for patients with NSCLC and look forward to moving into Phase III."

Capoxigem has been shown to potently inhibit COX-2-derived PGE2 production, reversing the PGE2-dependent epithelial-mesenchymal transition (EMT) process and the associated progression and metastasis of solid tumors. Reversal of EMT has important implications for the treatment of NSCLC using COX-2 inhibitors in combination with other agents.

Apricoxib is being studied in another Phase II clinical trial evaluating its use in combination with chemotherapy as second-line therapy for NSCLC. This trial utilizes a patient selection methodology similar to APRiCOT-L. Additionally, the company completed enrollment in late 2010 in a Phase
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tragara Pharmaceuticals Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
2. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
3. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
4. Treating Depression Prolongs Life for Older People with Diabetes
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Bayers Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
8. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
9. Dendreon Announces Exercise and Closing of Overallotment Option
10. Pharmasset Announces Exercise of Underwriters Overallotment Option
11. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 25, 2015 Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ... by Technology, Imaging and by Application - Forecast to 2020" ... is expected to reach $13.1 Billion in 2020 from an estimated ... The market is dominated by North America ... , and Rest of the World (RoW). The cancer diagnostics ...
(Date:7/2/2015)... Mass. , July 2, 2015   ... and European retinal specialists identify less frequent dosing ... edema (DME), due to the burden on both ... anti-vascular endothelial growth factor (VEGF) injections, which are ... Allergan/Molecular Partners, abicipar pegol, which is in development ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
Breaking Medicine Technology:Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... MOUNTAIN VIEW, Calif., April 28, 2011 IRIDEX Corporation (NASDAQ: ... quarter 2011 financial results after the market closes on ... the Company will host a conference call with the investment community ... Thursday, May 5, 2011 to discuss the results ...
... April 28, 2011 PharmaNet Development Group, Inc., a ... generic drug and medical device companies, announced today that ... President, Corporate Quality Assurance. "We are ... Newman, MD, President, PharmaNet Development Group. "Valerie brings deep ...
Cached Medicine Technology:
(Date:7/3/2015)... Lenexa, KS (PRWEB) , ... July 03, 2015 ... ... firm dedicated exclusively to healthcare providers, has been retained to lead a national ... Okla. One of the top-ranked executive search firms in the healthcare industry, B. ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... Jennifer Renee ... First Choice Emergency Room , the largest network of independent freestanding emergency rooms in ... facility medical director of our Sienna Plantation facility,” said Executive Medical Director of First ...
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness and the ... members of the Red Deer community with free fitness training and indoor fitness boot ... food, events and entertainment raised thousands of charity dollars and ended with a $10,000 ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce ... 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt chain ... 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is located ...
(Date:7/2/2015)... ... July 02, 2015 , ... Many Fourth of July celebrations ... why Amica Insurance is sharing some tips to promote the proper use ... people go to the emergency room daily with fireworks-related injuries in the month surrounding ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:6 Fireworks Safety Tips from Amica Insurance 2
... are obsessed,with red-carpet fashion, but Hollywood based "Dentist to ... a critic,s eye for,the best and worst smiles., ... smiles are really easy to notice during red carpet ... The Oaks Center for Cosmetic,Dentistry., The most outstanding ...
... to Streamline Hospital,s Operations and Revenue ... ... a $1,billion-plus global services firm that specializes in enabling,transformation of its clients, ... with Mount Sinai Hospital of Queens,part of New York-based Mount Sinai Medical ...
... Hero may help reduce global warming by making people ... in the 2007 European Satellite Navigation Competition, sponsored by ... technology to track journeys. , Concerned about global warming, ... their generation of carbon dioxide (CO2). One option is ...
... Corp. and,customer PHI, Inc. celebrated the execution of ... and the milestone achievement of 20,000 fleet,hours with ... at,Heli-Expo. Sikorsky Aircraft is a subsidiary of United ... http://www.newscom.com/cgi-bin/prnh/20060403/SIKORSKYLOGO ), Under the options contract, ...
... Ore. Oregon Health & Science University Cancer Institute ... men with advanced prostate cancer can take a much-needed ... randomized study, led by principal investigator Tomasz Beer, M.D., ... the Grover C. Bagby Endowed Chair for Cancer Research, ...
... 25 In response to the,Centers for Medicare ... this week, Kidney Care Partners (KCP) -- an ... manufacturers,working together to improve quality of care for ... CMS for issuing its long-awaited,report which recognizes the ...
Cached Medicine News:Health News:Keane Wins Revenue Cycle Management Implementation With Mount Sinai Hospital of Queens 2Health News:Keane Wins Revenue Cycle Management Implementation With Mount Sinai Hospital of Queens 3Health News:Tracking your carbon footprint 2Health News:Tracking your carbon footprint 3Health News:Sikorsky Aircraft and PHI Celebrate Fleet Expansion and 20K Milestone at Heli-Expo 2Health News:OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer 2Health News:Statement by Dr. Edward Jones, Chairman of Kidney Care Partners in Response to CMS Payment Bundling Report 2Health News:Statement by Dr. Edward Jones, Chairman of Kidney Care Partners in Response to CMS Payment Bundling Report 3
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
Medicine Products: